Stuart Therapeutics (Stuart) announced today that the U.S. Food and Drug Administration (FDA) has completed its review of an Investigational New Drug (IND) application for Stuart’s investigational product ST-100, a topical drop formulation designed to treat ocular surface diseases, including dry eye disease, an indication that affects nearly 10% of the United States population. As a result of this review, the FDA has issued a No-Holds, Study May Proceed letter to Stuart, permitting the company to begin its Phase 2 clinical trial on ST-100.